Phase 1 Trial for Primary Biliary Cholangitis Therapy Produces Promising Results
Albireo Pharma Inc. has just announced the results from their Phase 1 clinical trial for A3907, an ASBT inhibitor. The study produced positive results, achieving its primary and secondary endpoints. Researchers…